Arcus Biosciences (NYSE:RCUS) COO Sells $221,223.28 in Stock

by · The Markets Daily

Arcus Biosciences, Inc. (NYSE:RCUS – Get Free Report) COO Jennifer Jarrett sold 9,983 shares of Arcus Biosciences stock in a transaction on Wednesday, December 17th. The stock was sold at an average price of $22.16, for a total value of $221,223.28. Following the transaction, the chief operating officer owned 193,024 shares in the company, valued at approximately $4,277,411.84. This represents a 4.92% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Jennifer Jarrett also recently made the following trade(s):

  • On Tuesday, December 16th, Jennifer Jarrett sold 11,225 shares of Arcus Biosciences stock. The stock was sold at an average price of $21.88, for a total transaction of $245,603.00.
  • On Monday, October 6th, Jennifer Jarrett sold 12,500 shares of Arcus Biosciences stock. The shares were sold at an average price of $14.54, for a total transaction of $181,750.00.
  • On Wednesday, October 8th, Jennifer Jarrett sold 37,792 shares of Arcus Biosciences stock. The stock was sold at an average price of $15.05, for a total value of $568,769.60.

Arcus Biosciences Trading Down 1.2%

Shares of Arcus Biosciences stock traded down $0.26 during trading hours on Thursday, hitting $22.02. The company’s stock had a trading volume of 1,175,874 shares, compared to its average volume of 1,200,446. The stock has a market cap of $2.38 billion, a price-to-earnings ratio of -6.40 and a beta of 0.75. The company has a debt-to-equity ratio of 0.22, a quick ratio of 3.65 and a current ratio of 3.65. Arcus Biosciences, Inc. has a twelve month low of $6.50 and a twelve month high of $26.40. The firm has a fifty day moving average of $20.82 and a 200-day moving average of $13.98.

Arcus Biosciences (NYSE:RCUS – Get Free Report) last released its quarterly earnings results on Tuesday, October 28th. The company reported ($1.27) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.33) by $0.06. Arcus Biosciences had a negative net margin of 136.40% and a negative return on equity of 68.17%. The business had revenue of $26.00 million for the quarter, compared to the consensus estimate of $19.89 million. During the same period in the previous year, the firm earned ($1.00) EPS. The business’s revenue was down 45.8% on a year-over-year basis. Research analysts forecast that Arcus Biosciences, Inc. will post -3.15 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Vanguard Group Inc. increased its holdings in shares of Arcus Biosciences by 24.1% in the 1st quarter. Vanguard Group Inc. now owns 6,687,800 shares of the company’s stock worth $52,499,000 after acquiring an additional 1,298,584 shares during the period. Charles Schwab Investment Management Inc. raised its stake in shares of Arcus Biosciences by 23.2% during the first quarter. Charles Schwab Investment Management Inc. now owns 714,002 shares of the company’s stock valued at $5,605,000 after purchasing an additional 134,379 shares in the last quarter. Maryland State Retirement & Pension System lifted its holdings in Arcus Biosciences by 10.9% in the first quarter. Maryland State Retirement & Pension System now owns 20,202 shares of the company’s stock worth $159,000 after purchasing an additional 1,986 shares during the period. Swiss National Bank lifted its holdings in Arcus Biosciences by 35.9% in the 1st quarter. Swiss National Bank now owns 133,596 shares of the company’s stock valued at $1,049,000 after acquiring an additional 35,300 shares during the last quarter. Finally, Invesco Ltd. raised its holdings in shares of Arcus Biosciences by 24.5% in the 1st quarter. Invesco Ltd. now owns 254,024 shares of the company’s stock worth $1,994,000 after purchasing an additional 50,037 shares in the last quarter. 92.89% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the company. UBS Group reissued a “buy” rating on shares of Arcus Biosciences in a research report on Monday. Wedbush set a $35.00 price target on shares of Arcus Biosciences and gave the stock an “outperform” rating in a report on Wednesday, October 29th. Bank of America increased their price objective on shares of Arcus Biosciences from $17.00 to $26.00 and gave the company a “neutral” rating in a research report on Friday, November 28th. Wall Street Zen raised Arcus Biosciences from a “sell” rating to a “hold” rating in a research report on Sunday. Finally, HC Wainwright increased their price target on shares of Arcus Biosciences from $28.00 to $32.00 and gave the company a “buy” rating in a research note on Friday, December 12th. Eight investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $28.89.

Get Our Latest Analysis on RCUS

About Arcus Biosciences

(Get Free Report)

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.

Recommended Stories